212 related articles for article (PubMed ID: 17512238)
1. Management of neovascular age-related macular degeneration.
Schmidt-Erfurth UM; Pruente C
Prog Retin Eye Res; 2007 Jul; 26(4):437-51. PubMed ID: 17512238
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
[TBL] [Abstract][Full Text] [Related]
3. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
Karska-Basta I; Kubicka-Trzaska A; Oleksy P; Romanowska-Dixon B
Przegl Lek; 2009; 66(11):972-5. PubMed ID: 20297641
[TBL] [Abstract][Full Text] [Related]
4. Ranibizumab: Phase III clinical trial results.
Rosenfeld PJ; Rich RM; Lalwani GA
Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
[TBL] [Abstract][Full Text] [Related]
5. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration: past, present and future directions.
Smith BT; Joseph DP; Grand MG
Curr Opin Ophthalmol; 2007 May; 18(3):240-4. PubMed ID: 17435433
[TBL] [Abstract][Full Text] [Related]
7. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
8. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
10. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
11. Current treatment of age-related macular degeneration.
Zarbin M; Szirth B
Optom Vis Sci; 2007 Jul; 84(7):559-72. PubMed ID: 17632299
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of photographic screening for neovascular age-related macular degeneration.
Maberley DA; Isbister C; Mackenzie P; Aralar A
Eye (Lond); 2005 Jun; 19(6):611-6. PubMed ID: 15184945
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for neovascular age-related macular degeneration: state of the art.
Donati G
Ophthalmologica; 2007; 221(6):366-77. PubMed ID: 17947822
[TBL] [Abstract][Full Text] [Related]
14. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
15. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration.
Verma L; Das T; Binder S; Heriot WJ; Kirchhof B; Venkatesh P; Krebs I; Stolba U; Jahn C; Feichtinger H; Kellner L; Krugluger H; Pawelka I; Frohner U; Kruger A; Li W; Tewari HK
Indian J Ophthalmol; 2000 Dec; 48(4):263-78. PubMed ID: 11340884
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
17. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.
Grisanti S; Tatar O
Prog Retin Eye Res; 2008 Jul; 27(4):372-90. PubMed ID: 18621565
[TBL] [Abstract][Full Text] [Related]
18. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
19. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration.
Hayashi H; Yamashiro K; Tsujikawa A; Ota M; Otani A; Yoshimura N
Am J Ophthalmol; 2009 Jul; 148(1):83-9.e1. PubMed ID: 19327745
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
Brown DM; Regillo CD
Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
